A detailed history of Metropolitan Life Insurance CO transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Metropolitan Life Insurance CO holds 1,949 shares of AXSM stock, worth $156,329. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,949
Previous 2,042 4.55%
Holding current value
$156,329
Previous $162,000 4.32%
% of portfolio
0.01%
Previous 0.01%

Shares

34 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$69.39 - $97.64 $6,453 - $9,080
-93 Reduced 4.55%
1,949 $155,000
Q3 2023

Nov 14, 2023

BUY
$69.25 - $82.21 $18,282 - $21,703
264 Added 14.85%
2,042 $142,000
Q1 2023

May 15, 2023

SELL
$58.39 - $75.0 $11,853 - $15,225
-203 Reduced 10.25%
1,778 $109,000
Q4 2022

Jun 14, 2023

BUY
$39.94 - $79.72 $8,107 - $16,183
203 Added 11.42%
1,981 $153 Million
Q4 2022

Mar 30, 2023

BUY
$39.94 - $79.72 $10,304 - $20,567
258 Added 14.97%
1,981 $152,000
Q4 2022

Feb 15, 2023

BUY
$39.94 - $79.72 $10,304 - $20,567
258 Added 14.97%
1,981 $152,000
Q3 2022

Jun 14, 2023

SELL
$36.06 - $69.85 $1,983 - $3,841
-55 Reduced 3.09%
1,723 $76.9 Million
Q3 2022

Mar 30, 2023

SELL
$36.06 - $69.85 $6,707 - $12,992
-186 Reduced 9.74%
1,723 $76,000
Q3 2022

Nov 14, 2022

SELL
$36.06 - $69.85 $6,707 - $12,992
-186 Reduced 9.74%
1,723 $77,000
Q2 2022

Jun 20, 2023

BUY
$21.74 - $46.75 $2,847 - $6,124
131 Added 7.37%
1,909 $73,000
Q1 2022

Jun 20, 2023

BUY
$23.7 - $41.39 $3,104 - $5,422
131 Added 7.37%
1,909 $79,000
Q1 2022

Mar 30, 2023

SELL
$23.7 - $41.39 $152,604 - $266,510
-6,439 Reduced 77.13%
1,909 $79,000
Q1 2022

May 12, 2022

SELL
$23.7 - $41.39 $152,604 - $266,510
-6,439 Reduced 77.13%
1,909 $79,000
Q4 2021

Jun 21, 2023

BUY
$30.7 - $43.36 $201,699 - $284,875
6,570 Added 369.52%
8,348 $315,000
Q3 2021

Jun 21, 2023

BUY
$19.91 - $68.26 $130,808 - $448,468
6,570 Added 369.52%
8,348 $275,000
Q2 2021

Jun 21, 2023

BUY
$50.63 - $73.5 $332,639 - $482,895
6,570 Added 369.52%
8,348 $563,000
Q2 2021

Mar 30, 2023

BUY
$50.63 - $73.5 $17,517 - $25,431
346 Added 4.32%
8,348 $563,000
Q2 2021

Aug 16, 2021

BUY
$50.63 - $73.5 $422,254 - $612,990
8,340 Added 104250.0%
8,348 $563,000
Q1 2021

Jun 26, 2023

BUY
$55.91 - $81.44 $347,983 - $506,882
6,224 Added 350.06%
8,002 $453 Million
Q1 2021

Mar 30, 2023

SELL
$55.91 - $81.44 $12,467 - $18,161
-223 Reduced 2.71%
8,002 $453,000
Q1 2021

May 14, 2021

SELL
$55.91 - $81.44 $459,412 - $669,192
-8,217 Reduced 99.9%
8 $453,000
Q4 2020

Jun 22, 2023

BUY
$66.31 - $86.52 $427,500 - $557,794
6,447 Added 362.6%
8,225 $670,000
Q3 2020

Jun 26, 2023

BUY
$68.34 - $85.84 $440,587 - $553,410
6,447 Added 362.6%
8,225 $586,000
Q2 2020

Jun 26, 2023

BUY
$49.87 - $98.69 $321,511 - $636,254
6,447 Added 362.6%
8,225 $676,000
Q1 2020

Jul 12, 2023

BUY
$41.2 - $101.31 $265,616 - $653,145
6,447 Added 362.6%
8,225 $483,000
Q1 2020

Mar 30, 2023

BUY
$41.2 - $101.31 $24,637 - $60,583
598 Added 7.84%
8,225 $483,000
Q1 2020

May 15, 2020

BUY
$41.2 - $101.31 $24,637 - $60,583
598 Added 7.84%
8,225 $484,000
Q4 2019

Jul 12, 2023

BUY
$16.71 - $106.24 $97,736 - $621,397
5,849 Added 328.97%
7,627 $788,000
Q4 2019

Mar 30, 2023

SELL
$16.71 - $106.24 $13,969 - $88,816
-836 Reduced 9.88%
7,627 $788,000
Q4 2019

Feb 14, 2020

SELL
$16.71 - $106.24 $13,969 - $88,816
-836 Reduced 9.88%
7,627 $788,000
Q3 2019

Jul 12, 2023

BUY
$20.24 - $29.16 $135,304 - $194,934
6,685 Added 375.98%
8,463 $171,000
Q3 2019

Mar 30, 2023

BUY
$20.24 - $29.16 $131,195 - $189,015
6,482 Added 327.21%
8,463 $171,000
Q3 2019

Nov 14, 2019

BUY
$20.24 - $29.16 $171,291 - $246,781
8,463 New
8,463 $171,000
Q2 2019

Jul 12, 2023

BUY
$13.46 - $25.75 $915 - $1,751
68 Added 3.82%
1,846 $47.5 Million

Others Institutions Holding AXSM

About Axsome Therapeutics, Inc.


  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $3.44B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.